This randomized control trial aims to evaluate the effect of transcutaneous auricular vagal nerve stimulation in patients with irritable bowel syndrome. The intervention will be 8 weeks of treatment with a vagal nerve stimulator. The main objectives are: * To evaluate the clinical response, defined as a decrease of at least 50 points on the IBS-SSS questionnaire, of the treatment. * To ascertain whether the autonomic-vagal neurosignature, derived from pre-treatment registration of symptom profiles, autonomic responses and imaging of neuronal activity as a reaction to stress is able to predict therapeutic response to tVNS accurately. * To evaluate the effect of treatment on quality of life * To evaluate the effect of treatment on depression * To evaluate the effect of treatment on anxiety Participants will be asked to wear a wearable (Fitbit) and fill out a daily questionnaire for one week. Thereafter, a functional brain MRI will be performed. In the intervention group patients will receive transcutaneous nerve stimulation for 8-weeks at home. The comparison group will receive the same device but with a non-conducting electrode. Patients fill out weekly questionnaires during the treatment period and at follow-up moments 3 and 6 months after finishing the treatment period.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
166
Transcutaneous Auricular Vagal Nerve Stimulation
Sham stimulation with a non-conduction electrode
Maastricht University
Maastricht, Limburg, Netherlands
RECRUITINGClinical meaningful decrease in severity of GI-symptoms
Measuring IBS-SSS, defined as a decrease of at least 50 points
Time frame: at the end of the 8 week treatment period
Predictive value of neuro-signature
The value of the multimodal neuro-signature in the prediction of clinical response to tVNS in IBS-patients.
Time frame: at the end of the 8 week treatment period
adverse events
Number and severity of adverse events
Time frame: at the end of the 8 week treatment period
Anxiety/depression
Symptoms of anxiety and depression measured using PHQ-9 and GAD-7
Time frame: at the end of the 8 week treatment period
Cost-effectiveness
Direct and indirect costs made during the treatment period
Time frame: at follow up moment 2 (6 months after 8 week treatment period)
Time the device was used
The amount of time patients used the tVNS device
Time frame: at the end of the 8 week treatment period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.